Britain's dairy industry is doomed unless it takes more effective steps to control the spread of endemic diseases like tuberculosis and bovine virus diarrhoea, according to a leading cattle vet.
At a conference on infectious disease at the Royal Veterinary College last week, Devon practitioner Dick Sibley warned that the management and economic trends in the UK dairy industry are increasing the risk of disease transmission - and its potential impact once it does enter a herd.
Figures he obtained from the British Cattle Movements Service show that about four million cattle, or half the total UK cattle herd, are moved from one premises to another each year. Those being sent for slaughter were unlikely to spread infections but moving cattle of unknown disease status to new premises greatly increased the risk of bringing in new diseases. "If you set out to design a system that guarantees that we will continue to have problems with endemic disease then I could not think of a better one than this," he said.
Cattle numbers are increasing in those areas like Devon and Cheshire which already have among the highest population densities for dairy animals in the world - and are also the main hot spots in the current bovine TB epidemic. Farmers feel compelled to buy in heifers from as far afield as Germany and Holland to replace animals culled as TB reactors, as they will lose bonus payments from customers who demand that they maintain constant levels of production.
Several other factors also increase the likely impact of disease in a previously healthy herd - the concentration of cattle numbers into fewer but larger units, the growing emphasis on cattle kept indoors all year round and breeding for high yielding animals that are more vulnerable to disease. Meanwhile, a shortage of skilled manpower means that half the available stockmen are shared between farms and can therefore be responsible for bringing in disease.
But farmers have little or no control over some of the more important risk factors - particularly movements of badgers and the presence of diseased herds on neighbouring premises. "So these farmers with big herds in high density areas and neighbours that have the disease are done for unless we can do something serious to manage the risks."
Dairy farmers can work with their veterinary advisers to reduce risk using the four main pillars of disease control - improved biosecurity, better surveillance, appropriate vaccination and containment of disease transmission within the herd. But diseases also had to be tackled on a national level and if DEFRA is unwilling to take on the task, he proposed the creation of an independent livestock disease agency with sufficient staff and resources to carry out its remit. The costs of running such a body should be shared among all those stakeholders with an interest in preserving an economically viable dairy industry, including, for example the cereal producers who provide the dairy industry with much of its food materials, he suggested.
The RCVS issued a reminder today that there is just over a month left before the 1 April deadline for all veterinary practice premises from which medicines are to be supplied to be registered with the College.
Just over 4,500 premises have applied for registration since November 2008. This includes about 750 premises not previously listed with the College, demonstrating the usefulness of the process, which will enable the government to fulfil its obligations under European law to maintain and improve traceability of, and accountability for, veterinary medicines.
From 1 April it will be an offence for a veterinary surgeon to supply a veterinary medicinal product from any practice premises not registered with the RCVS. On conviction, those committing the offence may be liable to prosecution, which may include a fine or prison sentence. Veterinary surgeons convicted of criminal offences are also considered by the College's Preliminary Investigation Committee to decide whether the conviction would affect the individual's fitness to practise and should be referred to the Disciplinary Committee.
In addition to ensuring their practice premises are registered, veterinary surgeons also need to keep a record of other places where medicines are stored, so these can be considered during an inspection - such as vets' homes or cars, or perhaps a charity premises from which veterinary work is carried out and where medicines are stored. Such records will not be published, although some of those premises may need to be registered in their own right.
Practices accredited under the RCVS Practice Standards Scheme will be inspected by the RCVS; non-compliance with medicines standards will be dealt with under the rules of the Scheme. The Veterinary Medicines Directorate (VMD) will carry out inspections of other registered premises to ensure compliance with the Veterinary Medicines Regulations. Where non-compliance is noted, the VMD will take a proportionate enforcement approach ranging from issuing advice to, where appropriate, serving an improvement notice or seizing medicines.
TwistPak bottles have a hygienic interlock at the bottom, which allows them to be connected with a twist, creating one single mixing chamber which fits in all standard vaccination devices.
Currently, freshly mixing two vaccines requires a transfer needle.
Boehringer says the TwistPak bottle simplifies the mixing process while retaining the flexibility of using the products as a monovalent or combined vaccine.
TwistPak was jointly created with the industrial design and product development company DESIGNquadrat and awarded a Red Dot Design Award 2021 in the product design category.
Eva Joras, Global Brand Manager at Boehringer Ingelheim said: “TwistPak revolutionizes how vaccines are mixed.
"The mixing platform combines the best of both worlds: the unparalleled quality and efficacy of freshly mixed vaccines with the convenience of ready-to-use solutions.
TwistPak will be globally available in all registered presentation sizes starting May this year.
According to the FSA figures, 24.4% (758,263) of sheep and goats slaughtered between April and June this year had their throats cut without first being made insensible to pain, up from 15% in 2013, when the EU and UK-adopted legislation allowing an exemption for animals that are slaughtered for religious purposes came into force.
The number of chickens slaughtered without pre-stunning rose from 3% in 2013 to 18.5% (45,396,583) in 2017.
The BVA President Gudrun Ravetz said: "This huge increase in the number of sheep, goats and poultry that are not stunned or not stunned effectively before slaughter is a grave concern to our profession. Millions of individual animals are affected, making this a major animal welfare issue.
"The supply of meat from animals that have not been stunned massively outstrips the demand from the communities for which it is intended and is entering the mainstream market unlabelled.
"In the light of these official figures we reiterate our call for all animals to be stunned before slaughter. If slaughter without stunning is still to be permitted, any meat from this source must be clearly labelled and the supply of non-stun products should be matched with demand."
Welfare at slaughter is one of the UK’s most pressing health and welfare concerns for vets, according to the BVA’s latest member survey. The association has long campaigned for the re-introduction of law that guarantees all animals are stunned before slaughter on the grounds of animal welfare. While legislation exists to permit slaughter without pre-stunning, the BVA is calling for any meat or fish from this source to be clearly labelled to enable customers to understand the choice they are making when buying such products.
Photo: © Nevit Dilmen - Own work, Attribution-Share Alike 3.0 Unported
Loseley, the ice-cream maker, has announced that it has developed a new way of making flavoured ice-cream by adapting the diet fed to its cows.
The first variety to be made using the new technique is 'Eton Mess', for which the company's herd is being fed a diet of strawberries and meringues.
Loseley says its cattle - which are housed at the Beechdean Dairies farm in Buckinghamshire - have already been feeding on the ingredients found in the much loved pudding for over a year, to ensure their milk supply is infused with the strawberry and meringue flavours. Apparently, huge amounts of strawberries are having to be air-freighted into the UK in order to ensure an uninterrupted supply through the seasons.Andrew Howard Managing Director of Beechdean Dairies said: "We have been perfecting the quantities in the cattle feed for over 18 months to perfect the Eton Mess flavour. The cows need to be fed just the right quantities of meringues, strawberries, fat and hay to make the perfect Eton Mess ice cream. We believe ice cream should be great quality, tasty and interesting. Our products will always deliver against these criteria."Vince Bamford, Fast Moving Consumer Goods Editor at The Grocer, the UK's leading grocery trade magazine said: "Loseley's flavour development process is cutting edge - I have tasted the product and it is delicious. It is an exciting innovation for the ice cream category."
Ceva Animal health has launched Marbox, a broad-spectrum anti-infective, based on marbofloxacin, for the rapid treatment of bovine mastitis and respiratory disorders. According to the company, Marbox effectively provides two products in one bottle because it can be used as a high dose single injection or administered at a lower dose over several days.
Ceva says mastitis and respiratory disorders currently account for around 60% of antimicrobial prescriptions. Marbox can be used intramuscularly as a single injection for the treatment of respiratory infection. Alternatively it can be used for the treatment of acute mastitis; intravenously for the first injection and then subcutaneously at a lower dose over three days. It has a milk withdrawal of just 36 hours after subcutaneous injection.
Marbox is presented in an ergonomic CLAS vial which makes for light and shock-resistant handling, resulting in fewer breakages and reduced costs. It is available in 100 and 250 vial sizes and contains 100mg marbofloxacin per ml.
Marbox can be used in combination with Meloxidyl, Ceva's new, single shot anti-inflammatory. The product joins Ceva's bovine range of anti-infectives, which includes Cevaxel, Florkem and Spectam Injectable.
For further product information contact CEVA Animal Health Ltd, 90 The Broadway, Chesham, Bucks, HP5 1EG, telephone 01494 781510 or visit the website at http://www.ceva.uk.com/
Ceva Animal Health has launched PRID Delta, described as an improved intra-vaginal progesterone device for the synchronisation of oestrus in cycling and non-cycling cattle.
The company says it has used its 35 years of expertise in cattle fertility to develop PRID Delta, and that trials have demonstrated that the new device provides optimal progesterone release, preserved efficacy and high retention rates.
Ceva claims the special triangular shape and bi-material fabric of PRID Delta ensures maximum contact with vaginal mucosa to release optimal levels of progesterone at insertion and during treatment. The new PRID Delta continues to give a bigger progesterone peak after insertion as with the original PRID.
According to the company, clinical and field trials observing oestrus occurrence and fertility at fixed time artificial insemination have shown a preserved efficacy for PRID Delta. PRID Delta is licensed for oestrus synchronisation in both cycling and non cycling cows. It is licensed for fixed time AI. Trials have also confirmed that PRID Delta is quick and easy to insert, is well tolerated and has a retention rate of over 97%.
Ceva has recently introduced a new website www.reprology.com/ for technical advice on the best solutions for the management of cattle reproduction. For further information contact your Ceva sales representative or Ceva Animal Health Ltd, 90 The Broadway, Chesham, Bucks, HP5 1EG, telephone 01494 781510 or visit the website at www.ceva.uk.com/
Outstanding veterinary surgeons, veterinary nurses, animal welfare professionals and animal welfare teams can now be nominated to receive an award by their peers and the general public. Nominees can come from all walks of life, all ages, and from anywhere in the world.
The award categories include:
The Chris Laurence Vet of the Year Award supported by Your Dog and Your Cat magazinesThis award is in recognition of a veterinary surgeon working in practice that follows the footsteps of head judge, Chris Laurence, by educating pet owners and consistently demonstrating their commitment to the continued improvement of animal welfare.
Vet Nurse of the Year supported by Agria Pet InsuranceThis award is to give recognition to a veterinary nurse working in practice, who has shown real commitment to improving and championing excellent animal welfare within their surgery.
Charity Team of the Year supported by PDSAThis award is for an awe-inspiring team whose drive, passion and dedication has changed the lives of animals for the better, improving the standard of animal welfare where they can and working tirelessly to promote and champion their cause.
Charitable Contribution of the Year supported by Blue Cross This award is for an individual who works within a charity, either in a paid or voluntary role, who is consistently driven to the best of their ability, with a single-minded goal of helping save and improve the lives of animals in need.
Farm Animal Welfare Award supported by R.A.B.I. and NADISThis award is for an individual or team which have dedicated their careers to the health and welfare of production animals.
International Cat Care Welfare Award supported by International Cat CareThis award recognises an individual who has made a significant contribution to the development of feline welfare. The recipient of the award is chosen by International Cat Care and therefore the category is not open to nominations.
Since the first Ceva Awards in 2010, hundreds of people and teams have been nominated, with the winners decided by a panel of judges including Christopher Laurence MBE BVSc and James Yeates, chief veterinarian at RSPCA.
The winners and runners up will be honoured at a ceremony taking place on the eve of BSAVA Congress on 4th April 2018.
Ceva Animal Health managing director, Cuneyt Seckin said: "Over the last eight years we have been consistently humbled by the inspirational nominations that we receive from all over the world and we envisage this year to be no exception.
"The Ceva Animal Welfare Awards champion people involved in animal welfare, but they also raise awareness of this important work to wider audiences."
If there is a veterinary surgeon, nurse, animal welfare professional or animal welfare team that you feel deserves to be recognised for their ongoing commitment to animal welfare, visit www.cevawelfareawards.com to nominate.
Entries must be in by Friday 26 January 2018.
Forte highlights that Utertab's intrauterine administration allows it to act directly in the target tissue. It is presented in a perforated blister pack for better sealing.
Dr John Henderson, Large Animal Product Manager at Forte Healthcare Ltd said: "Given the need to use appropriate first-line antibacterial drugs where possible we are delighted to bring vets a new Tetracycline pessary, ‘Utertab’, for the treatment of metritis and retained foetal membranes.
"In-situ therapy for these conditions has more recently been neglected in favour of injectables but still has much to recommend it. We look forward to highlighting these benefits over the next few months."
For further information on Utertab 2000mg, contact your local Forte Territory Manager or enquiries@fortehealthcare.com.
The materials available include a scour management guide for farmers and a more detailed version for vets. They encourage a focus on three main areas for improved, sustained disease control: maximising calf immunity; identifying any causal agents and how to effectively manage an outbreak of calf scour on farm.
MSD Animal Health veterinary adviser Dr Kat Baxter-Smith (pictured right) said: "Even with good disease prevention protocols in place, calf scour outbreaks can still occur. But when they do, remedial action should focus on these three key areas to resolve the outbreak as quickly as possible and reduce the chances of another costly event happening in the future.
The company highlights a 202 survey of more than 300 farms, which found that over 80% of UK calf rearing units had seen a case of scour in the previous 12 months; with 50% of farms admitting to experiencing calf deaths due to the disease1. Costs are estimated at £57.94 per case but this does not include the longer-term impacts of the disease on future calf productivity.2,3
References
The BBC reports that a new strain of MRSA has emerged in British cows and is thought to be infecting humans.
For more on this story, click here.
The first, 'Factors that determine the success of a mastitis treatment' is tomorrow, Thursday 30th April, at 7:30pm. It will be presented by veterinary surgeon and researcher, Sofie Piepers.
The second webinar is titled 'Communication skills for effecting behaviour change with a focus on mastitis treatments'. Presented by Owen Atkinson, a vet with experience of the dairy industry around the world, the webinar will start at 7:30pm on Tuesday 5th May.
There will be opportunities to ask questions of both speakers at the end of each session.
For more information, visit: https://www.boehringer-academy.co.uk
Krka’s Farm Key Account Manager Charlotte Read said: “BRD remains a priority issue on farm and advising farmers on the management of BRD risks, and treatment options when needed, is a key task for farm vets.
"Flovuxin’s combined formulation is a high efficacy BRD treatment acting within six hours1, to improve treatment outcomes.”
Reference
The campaign came after the company surveyed livestock farmers in January, February and March this year, and found that cattle producers are struggling to implement changes.
The survey, which received 190 responses, investigated the extent to which beef and dairy producers are aware of methods to sustainably control parasites, how many are following best practice techniques, and what advice and support they need to make a change.
Sioned Timothy, Ruminant Technical Manager at Boehringer Ingelheim Animal Health said: “Reassuringly, 70% of respondents who are the main decision maker indicated that they were either very concerned or a little concerned about wormer resistance on farm. This level of awareness is positive since wormer resistance is on the rise, and the livestock industry must make changes to parasite control if we are to safeguard the effectiveness of wormers."
However, the survey indicated that farmers are not asking professionals such as their vet or SQP for advice on parasite control as much as they could. Only 55% of main decision maker respondents asked their vet for advice on parasite control planning as part of overall herd health planning, and that dropped to 21% for specific parasite control advice.
In addition, only 65% of main decision makers sought advice from an SQP when purchasing worming or fluke products, despite SQPs being qualified to provide parasite control advice at the point of prescription and supply.
Positively, over 60% of main decision maker respondents had already implemented some methods of sustainable parasite control, including quarantining and treating bought-in animals, managing pasture use, and calibrating and testing dosing guns.
However, more than half of the same respondents were aware of but had not implemented several other methods, including weighing or tracking growth rates of youngstock, testing individuals or groups of animals for parasites, and using preventative methods such as vaccinating for lungworm.
Sioned pointed out that nearly 25% of main decision makers had not implemented the calibration or testing of their wormer dosing guns, and a further 12% were not even aware of the practice. She said: “These producers are missing a simple opportunity to ensure that their cattle are dosed correctly. Under-dosing is one of the factors that drives resistance to anthelmintics on farm, and over-dosing increases costs unnecessarily.”
When respondents were asked why they haven’t implemented changes to their parasite control methods, 22% said they did not believe they needed to make changes, 20% don't have the necessary equipment or buildings, 37% said the cost of installing new/better equipment was a barrier, and 32% cited the cost of additional diagnostic tests or treatments.
The survey did highlight some positives. Victoria Hudson, Senior Brand Manager at Boehringer Ingelheim Animal Health, said: “Respondents indicated a good appetite for change provided they could access the appropriate advice and support, including implementing weighing and tracking growth rates of youngstock (53%), testing for parasite burdens in individual animals (52%) and testing for parasite burdens in groups of animals (43%).
“Just over a third of respondents felt they might be able to quarantine and treat bought-in cattle, manage pasture, and use vaccination or other preventative measures. However, only 31% of main decision maker respondents felt they could make the easiest and simplest change: calibrating and testing dosing guns before use.”
One method of sustainable parasite control, targeted selective treatment, where the best performing animals in a group are left untreated, was not well understood or implemented by respondents (30% had implemented, 36% were aware of it but had not implemented, and 33% were not aware of it), and just under 35% felt that even with advice and support they would not be able to implement this method within the next three years.
Victoria said: “Unsurprisingly, over half of main decision maker respondents cited they needed funding to support new equipment/infrastructure to help them make changes to their parasite control practices, but there is a desire for more advice and support.
“Nearly 49% want help in understanding the parasite challenges on their farm, 54% want advice on which changes will most benefit their cattle, and just over 33% want more information on the different types of wormer products.
“However, survey results were conflicting on how farmers would get this advice and support since only 13% wanted more visits from their vet, and 11% from their SQP, despite these professionals being best placed to provide advice at an individual farm level.
“It shows that there is more work to do to help beef and dairy producers make the most effective and sustainable changes to parasite control. This is why we have launched Change One Thing, a campaign to support farmers in understanding and implementing the options available to improve the sustainable control of parasites.”
The campaign is also calling on farm vets to Change One Thing, relating to the information, support and advice that they give livestock farmers.
Victoria said: “It can be difficult for vets to have conversations with farmers about making changes to their parasite control practices, so we urge them to think about changing their approach to discussing the topic, especially if their client/customer has so far resisted making any changes.
“Being inquisitive, and asking questions, can be more effective than ‘telling’, and it’s important that farmers believe in the need to make the change, and that they can practically do it. Even small changes can make a big difference, and testing and trailing strategies tailored to an individual farm will help the farmer to see the benefits for themselves.”
Boehringer says that changes that farmers could make to improve their parasite control in a sustainable way, include:
Resources for farmers, vets and SQPs to Change One Thing are available on the Beat the Parasites website: www.beattheparasites.com/change-one-thing.
The British Veterinary Association has launched a guidance poster to encourage farm animal vets to use anthelmintics responsibly, following ongoing concern about the development of resistance to these medicines.
According to BVA, misuse of anthelmintics in grazing animals, leading to resistance, is an increasing problem, which has now become a serious threat to the health and welfare of animals.
In response to growing concerns the BVA's Medicines Group has produced a poster that will be distributed to BVA members inside the Veterinary Record (23 January 2010 issue) and will be available to download from the BVA website.
The poster, accompanied by additional online guidance, clearly outlines Do's and Don'ts in the use of anthelmintics and carries the strong message "Think Twice Before Prescribing Anthelmintics". The poster is intended for display in veterinary practices as a reminder to vets and their clients of the need for responsible use of these medicinal products.
The poster carries advice on encouraging farm health planning and worming strategies, targeting the drug used to the parasite, the importance of not underdosing, quarantining incoming animals, and investigating and reporting suspected cases of resistance to the Veterinary Medicines Directorate (VMD). It clearly tells vets not to treat unnecessarily and not to blanket treat.
Peter Jones, Chair of the BVA's Medicines Group, said: "Every use of anthelmintics increases the risk of resistance developing. Veterinary surgeons have a duty to ensure anthelmintic use is judicious and limited to circumstances when treatment can be effective, targeted and based on sound veterinary diagnosis.
"The BVA advises all vets to work with their farming clients to develop a farm health plan that encompasses an effective worming strategy and a full grazing management programme to reduce the need for treatment.
"Vets must also promote good worming practice to ensure dosage is based on accurate weight measurements. Underdosing is a major factor in the development of resistance."
Professor Bill Reilly, President of the BVA, added: "Action to minimise the development of resistance is urgent and essential and we hope this poster will serve as a constant reminder to vets to think twice before prescribing anthelmintics."
Avishield IB G1-13 is indicated for active immunisation of chicks to reduce the adverse effect on cilia caused by infectious bronchitis.
The vaccine is one of two targeting the IBV 793B serotype and, with the addition of this new claim, Avishield can now be administrated on broiler, broiler breeder and laying hen farms.
Avishield IB GI-13 is a lyophilisate for oculonasal suspension/use in drinking water which contains live avian infectious bronchitis virus variant strain V-173/11: 102.7-104.6 EID50.
It has an onset of immunity 10 days after vaccination and a duration of immunity of 56 days.
Johnny Wells West, poultry key account manager at Dechra Veterinary Products, said: “The new licence extension for Avishield IB G1-13 allows greater flexibility for poultry producers to protect their flocks against infectious bronchitis on broiler, broiler breeder and laying hen farms and it is welcome news for both Dechra and the poultry industry.”
For more information contact Johnny Wells West on 07584 175758 or visit http://www.dechra.co.uk/Avishield IB G1-13
Over the next few weeks, experts from the fields of veterinary science, academia and government will be offering sector-specific insight into key achievements, latest research and future action needed to tackle AMR through a number of blog posts published on www.bva.co.uk/BVA-blog.
Bloggers will include BVA President John Fishwick, presidents of several BVA specialist divisions, leading academics, and heads of the Responsible Use of Medicines in Agriculture Alliance (RUMA) and the National Office of Animal Health (NOAH), among others.
AMR poses a global threat to human and animal health and requires concerted efforts across the medical and veterinary professions to steward responsible use and prescription, as recognised in the UK Government-commission global Review on Antimicrobial Resistance, chaired by Lord O’Neill (May 2016).
The veterinary profession in the UK has been committed to the responsible use of antimicrobials, with the Chief Medical Officer publicly recognising the concerted efforts to reduce antibiotic usage in agriculture. BVA is a member of RUMA and has been working closely with stakeholders in government and industry to develop appropriate and evidence based targets across the livestock sector, which will be announced tomorrow (27 October) at a conference in London.
British Veterinary Association Senior Vice President Gudrun Ravetz said: "AMR is a serious global One Health issue that the veterinary profession is deeply concerned about, as it threatens our ability to treat animals and protect human health, and it is an issue BVA is addressing through joined-up working with UK governments, industry and other health sectors. Increased collaboration between the health sectors, underpinned by a commitment from each of us within the veterinary profession to maintain the highest standards of stewardship in using antimicrobials, most especially Critically Important Antibiotics, is the only way we can preserve these essential medicines for future generations.
"The blog series highlights various aspects of AMR by experts in their field, and we hope that throwing a spotlight on various sectors’ achievements so far and suggested steps for the future will help keep this important issue on all of our agendas, where it should be."
AMR discussions will continue at BVA Congress at the London Vet Show (16-17 November) with a Friday afternoon session on ‘The psychology of antimicrobial resistance: what can social science tell us?’, featuring David Brodbelt, Professor of Evidence-based Veterinary Medicine at Royal Veterinary College; Ian Donald,Emeritus Professor of Psychology and Director, Mulberry Research & Consulting Ltd, and Kristen Reyher, Senior Lecturer in Farm Animal Science at the University of Bristol.
To read Nigel Gibbens’s blog and other blogs from the series, see https://www.bva.co.uk/news-campaigns-and-policy/bva-community/bva-blog/safeguarding-the-future-of-antibiotics-is-our-moral-responsibility-as-vets/ and follow the ‘#AMRinfocus’ hashtag on social media.
The Animal Medicines Training Regulatory Authority (AMTRA) is launching its new Continuous Professional Development (CPD) scheme today, designed to ensure that the Authority's registered Suitably Qualified Persons (SQPs) keep up to date with the latest animal medicines information.
In order to maintain their SQP status, every SQP will have to achieve a minimum number of CPD points during each AMTRA CPD period, running for two years from July to June. However, in the initial stages of the scheme, this first period will run for 33 months, from October 2008 to June 2011, allowing AMTRA to fine tune the system if required and give its SQPs time to get used to the new structure.
During these CPD periods, SQPs are required to obtain a minimum number of CPD points depending on their SQP type:
SQP Type: Modules; VPS medicines supplied; CPD PointsR-SQP: FAM+EQM+CAM; All VPS Medicines; 70 pointsG-SQP: FAM+EQM; VPS-farm animals and equines only; 50 pointsK-SQP: FAM+CAM; VPS-farm and companion animals only; 50 pointsE-SQP: EQM+CAM; VPS-equines and companion animals only; 50 pointsL-SQP: FAM; VPS-farm animals only; 30 pointsJ-SQP: EQM; VPS-equines only; 30 pointsC-SQP: CAM; VPS-companion animals only; 30 points
(FAM - Farm Animal Module, EQM - Equine Module, CAM - Companion Animal Module)
In essence, this means that 20 points are required per animal group, plus a further 10 points. Dr Roger Dawson, Secretary of AMTRA comments, "There is no maximum number of CPD points that SQPs can accumulate and we will be encouraging them to gain the benefit of as much CPD as they can."
Those SQPs who do not achieve the minimum number of CPD points by the end of the period will not be eligible to renew their status for the following year. However, such SQPs will have the option of sitting an examination before the end of that CPD period in order to maintain their SQP status and eligible be to renew for the next year.
SQPs will have a range of avenues through which to gain CPD points, ranging from four types of AMTRA-accredited CPD Events, to online study and personal study. With CPD Events and online studies, accreditation and points will be awarded by the AMTRA CPD Accreditation Panel. With personal study, AMTRA accepts a degree of self-certification of this form of CPD, however the points gained in this way are limited to a relatively small proportion of the minimum required in a CPD period.
Throughout a CPD period, all SQPs are required to attend at least ONE CPD Event. These events will comprise a range of modules that will be assessed for coverage, of relevant topics ranging from legislation, regulations and prevalence & effects of parasites and pathogens, to control of disease management, resistance, warnings and SARS.
Dr Dawson says, "The new CPD scheme has the necessary flexibility to allow SQPs to gain the required CPD points via a number of routes, from accredited CPD events and online study to personal study. Furthermore, the structure of the scheme ensures that their studies will be properly assessed to ensure they have gained the necessary knowledge to secure their CPD points."
Boehringer Ingelheim Vetmedica has announced that it will be launching Bovela, a new viral diarrhoea (BVD) vaccine, to farmers during April 2015.
Allan Henderson from Boehringer said: "BVD remains the most common viral disease affecting cattle throughout Europe, despite vaccines being available for over 15 years. We asked farmers why this was the case and, without exception, they remarked that current vaccine protocols are unwieldy, requiring precise timings making them hard to follow.
"Bovela is a unique one-shot vaccine that can be used in cattle from three months of age and also whether pregnant or not. Other, currently available vaccines require a two-dose primary course with boosters annually or even every six months thereafter."
BVD is spread within herds and to new herds through the presence of persistently infected (PI) animals. PIs can look relatively healthy and show no outward signs of infection but, as they were exposed to the virus as a foetus, have become virus carriers. If they are born alive, they will shed virus consistently throughout their lives so perpetuating the cycle of infection.
Alan said: "The foetal control delivered by Bovela gives absolute confidence that cows will not produce PIs. This, alongside the drastically improved convenience will undoubtedly make Bovela the natural choice for many farmers, both on beef and dairy farms."
According to Boehringer, around 60% of cattle in the EU test positive for exposure to the BVD virus and, although BVD type 1 is currently the most common form, outbreaks of BVD type 2, were confirmed in 2013 and 2014 in Belgium, Germany and The Netherlands. BVD type 2 is generally a more serious disease, with high levels of mortality and while the virus has been identified in UK, it has not yet been identified as the cause of serious outbreaks of disease in cattle.
Alan said: "Bovela is the first and only vaccine in UK which has been proven to protect cattle from BVD type 1 and 2. It has been in development for 17 years and, gained a marketing authorisation following assessment of an unprecedented quantity of data generated in both beef and dairy herds.
"Work has looked at the efficacy of Bovela in preventing the production of PI calves and against type 1 and 2 BVD as well as confirming its efficacy in young calves as young as three months of age as their natural maternal protection wears off. Trials also confirmed vaccine safety generally and during various stages of pregnancy. We do not believe that any other BVD vaccine has been tested as rigorously."
The Veterinary Development Council (VDC) is conducting a survey to investigate the role of paraprofessionals and technicians in veterinary practice, and is asking vets in large animal, equine, and mixed practices to complete a short survey.
The VDC says that information from the survey will help inform discussions on the regulation of technicians.
The survey will take between 5 and 10 minutes to complete and can be found on the BVA website at www.bva.co.uk/vdc. The BVA has also emailed the survey directly to practices.
The survey has been devised by the VDC working group looking at the role of the veterinary-led team, chaired by BVA Past President Professor Bill Reilly. This is one of three working groups that will report to the VDC:
Professor Reilly said: "The relationship between veterinary surgeons and technicians is vital but it varies from practice to practice.
"The working group on the role of the veterinary-led team aims to take a snapshot of how services, such as artificial insemination and foot trimming, are currently delivered, and gauge how veterinary surgeons feel about other services being delivered by non-veterinarians in the future.
"I hope veterinary surgeons in large, mixed and equine practice will take 10 minutes to complete our survey to help us map the current use of technicians in veterinary practice and help shape our future discussions."
The recall was initiated because a visual inspection confirmed the possibility of particulate contamination which is not acceptable for an intravenous use preparation.
The recall is for the following batches only:
108AB Expiry 12/01/2023113H Expiry 16/03/2023
Ceva Animal Health Ltd is contacting veterinary surgeons, retailers and wholesale dealers to examine inventory and quarantine products subject to the recall.
For further information, contact Peter Kyte Business Unit Manager on +44 1494 781510.
The BVA has welcomed the decision to prohibit the advertising of antimicrobials directly to animal keepers from 2013 in a bid to reduce antimicrobial resistance.
The Veterinary Medicines Directorate (VMD) announced that the Veterinary Medicines Regulations will be revised next year. The change has come as a result of the European Commission's view that the UK did not correctly transpose the European Directive 2001/82/EC which prohibits the advertising of certain veterinary medicinal products to the 'general public'.
When the VMD consulted on proposals to restrict the advertising of antimicrobials to farmers in 2010 the BVA supported the measure as a sensible approach to the responsible use of antimicrobials.
In a letter to stakeholders the VMD explained that: "A number of interested parties from veterinary medicine hold the view that the advertising of antibiotics to keepers of animals leads to undue pressure to prescribe newer antibiotics, which can often be important in human medicine and are associated with the development of multiple resistances."
Peter Jones, President of the BVA, said: "The BVA has consistently argued for the restriction of advertising of antimicrobials to animal keepers and we believe this is the right decision.
"New antimicrobials are heavily advertised by pharmaceutical companies and there can be undue pressure put on veterinary surgeons by clients who want to try new products that promise good results, but which may not be appropriate from the point of view of responsible use.
"Antimicrobial resistance is a very serious issue for both animal and human health and we are pleased that the European Commission and the VMD have taken the view that the Regulations need to be revised.
"Ultimately, it is the veterinary surgeon who will make the decision on which veterinary products to use and vets will continue to work with their farm clients to ensure antimicrobials are used prudently and responsibly."
The 2009 edition of the NOAH Compendium Data Sheets for Animal Medicines is now being dispatched, free of charge, to each practice premises.
Meanwhile, the online version of the compendium (www.noahcompendium.co.uk), launched 3 years ago to provide a free and convenient source of information about animal medicines for both prescribers and consumers, has just had its 9 millionth page view. The site gets about 3000 visits a day.
Whilst it is possible to order additional print copies of the compendium, NOAH points out that the online version has the beauty of being updated every week with new products, indications and other data. Plus the site is searchable by active ingredient, species, therapeutic indication or text search.
NOAH chief executive Phil Sketchley said: "We try to make the online Compendium as useful and as quick and easy to use as it can be, and while we have received overwhelmingly positive feedback we are always interested to hear how you think it could work better for you, so we can keep this in mind for any future improvements".
Animalcare Ltd has launched Marbocare (marbofloxacin) 100mg/ml solution for injection, a third-generation fluoroquinolone for the treatment of E.coli mastitis and bovine respiratory disease (BRD) in cattle, and Metritis Mastitis Agalactia in pigs.
The company highlights the product's unique flexible dosage regimen of once daily injections for 3 days against E.coli mastitis and BRD, plus a single intramuscular (IM) high dose (8mg/100kg) for BRD.
Animalcare says this regimen, coupled with the flexibility of administration afforded by all three injection routes (intravenous IV, subcutaneous SC and IM), a low volume dose and good syringeability, all combine to offer ease of use; resulting in a reduction in handling and less stress for the cattle.
Developed for veterinary use only, Marbocare has broad spectrum activity against Gram+ve and Gram-ve pathogens. Animalcare says the product is especially effective against E.coli mastitis and the key bacterial pathogens associated with BRD, as well as M.bovis.
Marbocare has milk withdrawal times of 36 hours after the last treatment following the 3 day course and 72 hours after a single shot for BRD. Meat withdrawal is 6 days after multiple injections and 3 days after the single shot.
Marbofloxacin has proven efficacy in a comparative international, multi-centre, controlled, randomised field trial1 in 62 dairy cows with E.coli mastitis. Marbofloxacin cure rates were significantly higher than the control product. In respiratory disease it showed a more rapid clinical response in comparison to tilmicosin2, ceftiofur3 and oxytetracycline4. Marbofloxacin was shown to be well tolerated, leading to a fast return to appetite, liveweight gain and associated welfare benefits.
Marbocare is also licensed in the treatment of Metritis Mastitis Agalactia syndrome in pigs, given by IM injection, with a 4 day meat withdrawal.
Tony Liepman, Product Manager from Animalcare said: "Marbocare is competitively priced whether used on its own or alongside a single-dose anti-inflammatory such as Emdocam (meloxicam)."
Marbocare is a POM-V licensed product presented in 50 and 100ml multi-dose vials.